Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia.

Abstract excerpt

The β-blocker propranolol, originally designed for cardiological indications (angina, cardiac arrhythmias and high blood pressure), is nowadays, considered the most efficient drug for the treatment in infantile haemangiomas (IH), a vascular tumour that affects 5-10% of all infants. However, its potential therapeutic benefits in other vascular anomalies remain to be explored. In the present work we have assessed...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Activin Receptors, Type II
• Share to Adrenergic beta-Antagonists